On the primary endpoints of the study, combined cardiovascular mortality and worsening heart failure events (α = 0.04) were ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

The American Heart Association held its annual Scientific Sessions Nov. 16-18 in Chicago, where healthcare organizations and industry leaders presented the latest research on cardiovascular health.

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

The American Heart Association and the Arizona Cardinals gathered representatives from 12 local schools for cardiopulmonary ...

News on Inhibikase's promising treatments for PAH and Parkinson's Disease, supported by FDA approval and substantial funding.

A new type of therapy that "edits" a gene in patients with a rare heart condition has been shown to be safe and effective, ...

(HealthDay News) — For patients with obesity and prediabetes, 3 years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

Footage of a man being shoved into a wall by a police officer before being dragged through a front yard has been shared on social media, with SA Police confirming a formal complaint has been made ...